Trials Sponsors Conditions Drugs Pricing

Conditions

Obesity-Associated Insulin Resistance

Outcome Measures

Primary Outcomes (1)

Insulin Sensitivity
Dose response curve to insulin (measure as glucose infusion rate, mg/kg/min)
6 hours

Study Arms (2)

Moxonidine

EXPERIMENTAL

Moxonidine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks

Drug: Moxonidine 0.2 MG

Amlodipine

ACTIVE COMPARATOR

Amlodipine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks

Drug: Amlodipine 5 MG

Interventions

Moxonidine 0.2 MGDrug

Moxonidine 0.2 MG twice daily

Moxonidine

Amlodipine 5 MGDrug

Amlodipine 5 MG twice daily

Amlodipine

Eligibility Criteria

Age18 Years - 65 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Males and females of all races between 18 and 60 years of age
Hypertension defined by two or more properly measured seated blood pressure readings \>130/85 mmHg or currently on antihypertensive medication.

Sponsors & Collaborators

National Heart, Lung, and Blood Institute (NHLBI)
NIHcollaborator
Italo Biaggioni
Otherlead

Study Sites (1)

Vanderbilt University

Nashville, Tennessee, 37232, United States

MeSH Terms

Interventions

moxonidineAmlodipine

Intervention Hierarchy (Ancestors)

DihydropyridinesPyridinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Results Point of Contact

Title: Dr. Alfredo Gamboa
Organization: Vanderbilt University Medical Center

Study Officials

Italo Biaggioni, MD
Vanderbilt University Medical Center
PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee: Yes
Restrictive Agreement: No

Enrollment

10 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: RANDOMIZED
Masking: TRIPLE
Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose: BASIC SCIENCE
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: SPONSOR INVESTIGATOR
PI Title: Professor

Study Record Dates

First Submitted

March 16, 2020

First Posted

April 1, 2020

Study Start

February 23, 2021

Actual (reported)

Study Stopped

Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Results Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Moxonidine

Amlodipine

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Documents

Locations

Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Results Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Moxonidine

Amlodipine

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Documents

Locations